Amgen (AMGN) Stock Forecast, Price Target & Predictions
AMGN Stock Forecast
Amgen stock forecast is as follows: an average price target of $286.95 (represents a -13.69% downside from AMGN’s last price of $332.45) and a rating consensus of 'Buy', based on 22 wall street analysts offering a 1-year stock forecast.
AMGN Price Target
The average price target for Amgen (AMGN) is $286.95 based on 1-year price targets from 22 Wall Street analysts in the past 3 months, with a price target range of $380.00 to $182.00. This represents a potential -13.69% downside from AMGN's last price of $332.45.
AMGN Analyst Ratings
According to 22 Wall Street analysts, Amgen's rating consensus is 'Buy'. The analyst rating breakdown for AMGN stock is 0 'Strong Buy' (0.00%), 12 'Buy' (54.55%), 9 'Hold' (40.91%), 1 'Sell' (4.55%), and 0 'Strong Sell' (0.00%).
Amgen Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 07, 2024 | Mohit Bansal | Wells Fargo | $335.00 | $328.95 | 1.84% | 0.77% |
| Aug 06, 2024 | Terence Flynn | Morgan Stanley | $303.00 | $330.79 | -8.40% | -8.86% |
| Jun 14, 2024 | Gregory Renza | RBC Capital | $332.00 | $298.71 | 11.14% | -0.14% |
| May 17, 2024 | Jay Olson | Oppenheimer | $380.00 | $312.32 | 21.67% | 14.30% |
| May 09, 2024 | Salim Syed | Mizuho Securities | $235.00 | $307.31 | -23.53% | -29.31% |
| May 03, 2024 | Terence Flynn | Morgan Stanley | $310.00 | $315.19 | -1.65% | -6.75% |
| May 03, 2024 | Evan David Seigerman | BMO Capital | $355.00 | $278.39 | 27.52% | 6.78% |
| May 03, 2024 | Colin Bristow | UBS | $307.00 | $278.39 | 10.28% | -7.66% |
| May 03, 2024 | Carter Gould | Barclays | $300.00 | $278.39 | 7.76% | -9.76% |
| Apr 17, 2024 | Mohit Bansal | Wells Fargo | $320.00 | $265.11 | 20.71% | -3.74% |
The latest Amgen stock forecast, released on Aug 07, 2024 by Mohit Bansal from Wells Fargo, set a price target of $335.00, which represents a 1.84% increase from the stock price at the time of the forecast ($328.95), and a 0.77% increase from AMGN last price ($332.45).
Amgen Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 10 |
| Avg Price Target | - | $319.00 | $317.70 |
| Last Closing Price | $332.45 | $332.45 | $332.45 |
| Upside/Downside | -100.00% | -4.05% | -4.44% |
In the current month, the average price target of Amgen stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Amgen's last price of $332.45. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 07, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Aug 07, 2024 | William Blair | Outperform | Outperform | Hold |
| Aug 07, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Aug 07, 2024 | Wells Fargo | Overweight | Equal-Weight | Downgrade |
| Aug 06, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Aug 06, 2024 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Aug 06, 2024 | Argus Research | Buy | Buy | Hold |
| Aug 06, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Jul 19, 2024 | Jefferies | Buy | Buy | Hold |
| Jul 12, 2024 | UBS | Neutral | Neutral | Hold |
Amgen's last stock rating was published by Oppenheimer on Aug 07, 2024. The company gave AMGN a "Outperform" rating, the same as its previous rate.
Amgen Financial Forecast
Amgen Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $8.20B | $6.90B | $6.99B | $6.11B | $6.84B | $6.65B | - | $6.24B | $6.85B | $6.71B | $6.53B | $5.90B | $6.63B | $6.42B | $6.21B | $6.16B | $6.20B | $5.74B |
| Avg Forecast | $8.31B | $8.21B | $8.16B | $7.64B | $8.77B | $8.61B | $8.62B | $8.14B | $8.88B | $8.52B | $8.35B | $7.45B | $8.13B | $6.93B | $6.66B | $6.15B | $6.74B | $6.56B | $6.53B | $6.07B | $6.87B | $6.67B | $6.46B | $6.26B | $6.57B | $6.39B | $6.19B | $6.00B | $6.03B | $5.63B |
| High Forecast | $8.46B | $8.36B | $8.31B | $7.78B | $8.93B | $8.77B | $8.78B | $8.29B | $9.04B | $8.69B | $8.50B | $7.59B | $8.30B | $8.33B | $6.79B | $6.27B | $6.87B | $6.68B | $6.53B | $6.41B | $7.26B | $7.05B | $6.82B | $6.62B | $6.95B | $6.75B | $6.55B | $6.34B | $6.37B | $5.95B |
| Low Forecast | $8.10B | $8.01B | $7.96B | $7.45B | $8.56B | $8.40B | $8.41B | $7.94B | $8.66B | $8.42B | $8.15B | $7.27B | $7.98B | $6.73B | $6.50B | $6.00B | $6.58B | $6.40B | $6.53B | $5.91B | $6.69B | $6.50B | $6.29B | $6.10B | $6.41B | $6.22B | $6.04B | $5.85B | $5.88B | $5.49B |
| # Analysts | 9 | 7 | 11 | 7 | 6 | 12 | 6 | 6 | 7 | 14 | 7 | 9 | 10 | 18 | 15 | 9 | 10 | 16 | 8 | 11 | 9 | 9 | 14 | 5 | 5 | 5 | 5 | 5 | 4 | 4 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.01% | 1.00% | 1.05% | 0.99% | 1.01% | 1.01% | - | 1.03% | 1.00% | 1.01% | 1.01% | 0.94% | 1.01% | 1.01% | 1.00% | 1.03% | 1.03% | 1.02% |
Amgen's average Quarter revenue forecast for Mar 24 based on 9 analysts is $7.45B, with a low forecast of $7.27B, and a high forecast of $7.59B. AMGN's average Quarter revenue forecast represents a -9.08% decrease compared to the company's last Quarter revenue of $8.20B (Dec 23).
Amgen EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 7 | 11 | 7 | 6 | 12 | 6 | 6 | 7 | 14 | 7 | 9 | 10 | 18 | 15 | 9 | 10 | 16 | 8 | 11 | 9 | 9 | 14 | 5 | 5 | 5 | 5 | 5 | 4 | 4 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $1.27B | $2.02B | $2.68B | $3.98B | $2.16B | $2.76B | - | $1.97B | $3.32B | $3.30B | $3.20B | $2.98B | $3.07B | $3.41B | $3.26B | $3.26B | $2.99B | $3.10B |
| Avg Forecast | $3.38B | $3.34B | $3.32B | $3.11B | $3.57B | $3.50B | $3.51B | $3.32B | $3.61B | $3.47B | $3.40B | $3.28B | $3.31B | $2.82B | $2.71B | $2.98B | $2.75B | $3.24B | $2.66B | $2.71B | $3.14B | $2.95B | $1.59B | $3.24B | $2.69B | $2.91B | $2.90B | $2.91B | $2.84B | $2.98B |
| High Forecast | $3.44B | $3.40B | $3.38B | $3.17B | $3.64B | $3.57B | $3.57B | $3.38B | $3.68B | $3.54B | $3.46B | $3.93B | $3.38B | $3.39B | $2.76B | $3.57B | $2.80B | $3.89B | $2.66B | $3.25B | $3.77B | $3.54B | $1.91B | $3.89B | $3.23B | $3.49B | $3.48B | $3.49B | $3.41B | $3.58B |
| Low Forecast | $3.30B | $3.26B | $3.24B | $3.03B | $3.48B | $3.42B | $3.42B | $3.23B | $3.53B | $3.43B | $3.32B | $2.62B | $3.25B | $2.74B | $2.65B | $2.38B | $2.68B | $2.60B | $2.66B | $2.17B | $2.51B | $2.36B | $1.27B | $2.59B | $2.15B | $2.33B | $2.32B | $2.33B | $2.27B | $2.39B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.38% | 0.72% | 0.99% | 1.34% | 0.79% | 0.85% | - | 0.73% | 1.06% | 1.12% | 2.01% | 0.92% | 1.14% | 1.17% | 1.12% | 1.12% | 1.05% | 1.04% |
9 analysts predict AMGN's average Quarter EBITDA for Mar 24 to be $3.28B, with a high of $3.93B and a low of $2.62B. This is 157.82% upper than Amgen's previous annual EBITDA (Dec 23) of $1.27B.
Amgen Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 7 | 11 | 7 | 6 | 12 | 6 | 6 | 7 | 14 | 7 | 9 | 10 | 18 | 15 | 9 | 10 | 16 | 8 | 11 | 9 | 9 | 14 | 5 | 5 | 5 | 5 | 5 | 4 | 4 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $767.00M | $1.73B | $1.38B | $2.84B | $1.62B | $2.14B | - | $1.48B | $1.90B | $1.88B | $464.00M | $1.65B | $1.61B | $2.02B | $1.80B | $1.82B | $1.70B | $1.97B |
| Avg Forecast | $2.13B | $2.68B | $2.72B | $2.52B | $2.93B | $3.00B | $2.98B | $2.73B | $2.94B | $2.78B | $2.70B | $1.72B | $2.48B | $2.53B | $2.43B | $1.56B | $2.22B | $1.85B | $2.38B | $1.42B | $1.80B | $1.68B | $435.91M | $1.79B | $1.41B | $1.72B | $1.61B | $1.63B | $1.62B | $1.90B |
| High Forecast | $2.18B | $2.74B | $2.79B | $2.58B | $3.00B | $3.08B | $3.05B | $2.79B | $3.01B | $2.94B | $2.76B | $2.06B | $2.71B | $2.66B | $2.49B | $1.88B | $2.27B | $2.22B | $2.38B | $1.71B | $2.16B | $2.02B | $523.10M | $2.15B | $1.70B | $2.07B | $1.93B | $1.95B | $1.94B | $2.27B |
| Low Forecast | $2.06B | $2.59B | $2.64B | $2.43B | $2.83B | $2.91B | $2.89B | $2.64B | $2.85B | $2.62B | $2.61B | $1.38B | $2.32B | $2.32B | $2.35B | $1.25B | $2.15B | $1.48B | $2.38B | $1.14B | $1.44B | $1.35B | $348.73M | $1.43B | $1.13B | $1.38B | $1.28B | $1.30B | $1.30B | $1.52B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.31% | 0.68% | 0.57% | 1.82% | 0.73% | 1.16% | - | 1.04% | 1.06% | 1.12% | 1.06% | 0.92% | 1.14% | 1.17% | 1.12% | 1.12% | 1.05% | 1.04% |
Amgen's average Quarter net income forecast for Mar 24 is $1.72B, with a range of $1.38B to $2.06B. AMGN's average Quarter net income forecast represents a 124.33% increase compared to the company's last Quarter net income of $767.00M (Dec 23).
Amgen SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 7 | 11 | 7 | 6 | 12 | 6 | 6 | 7 | 14 | 7 | 9 | 10 | 18 | 15 | 9 | 10 | 16 | 8 | 11 | 9 | 9 | 14 | 5 | 5 | 5 | 5 | 5 | 4 | 4 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $2.27B | $1.35B | $1.29B | $1.26B | $1.57B | $1.29B | - | $1.23B | $1.43B | $1.30B | $1.38B | $1.25B | $1.77B | $1.35B | $1.29B | $1.32B | $1.51B | $1.22B |
| Avg Forecast | $1.79B | $1.77B | $1.76B | $1.65B | $1.89B | $1.85B | $1.86B | $1.75B | $1.91B | $1.83B | $1.80B | $1.43B | $1.75B | $1.49B | $1.44B | $1.30B | $1.45B | $1.28B | $1.41B | $1.18B | $1.35B | $1.17B | $1.30B | $1.36B | $1.55B | $1.15B | $1.15B | $1.17B | $1.44B | $1.18B |
| High Forecast | $1.82B | $1.80B | $1.79B | $1.68B | $1.93B | $1.89B | $1.89B | $1.79B | $1.95B | $1.87B | $1.83B | $1.72B | $1.79B | $1.79B | $1.46B | $1.56B | $1.48B | $1.54B | $1.41B | $1.42B | $1.62B | $1.40B | $1.56B | $1.63B | $1.86B | $1.38B | $1.38B | $1.41B | $1.73B | $1.41B |
| Low Forecast | $1.75B | $1.73B | $1.71B | $1.61B | $1.84B | $1.81B | $1.81B | $1.71B | $1.87B | $1.81B | $1.76B | $1.15B | $1.72B | $1.45B | $1.40B | $1.04B | $1.42B | $1.03B | $1.41B | $946.46M | $1.08B | $932.67M | $1.04B | $1.09B | $1.24B | $918.53M | $922.39M | $938.00M | $1.15B | $942.37M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.30% | 0.91% | 0.90% | 0.97% | 1.08% | 1.00% | - | 1.04% | 1.06% | 1.12% | 1.06% | 0.92% | 1.14% | 1.17% | 1.12% | 1.12% | 1.05% | 1.04% |
Amgen's average Quarter SG&A projection for Mar 24 is $1.43B, based on 9 Wall Street analysts, with a range of $1.15B to $1.72B. The forecast indicates a -37.05% fall compared to AMGN last annual SG&A of $2.27B (Dec 23).
Amgen EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 7 | 11 | 7 | 6 | 12 | 6 | 6 | 7 | 14 | 7 | 9 | 10 | 18 | 15 | 9 | 10 | 16 | 8 | 11 | 9 | 9 | 14 | 5 | 5 | 5 | 5 | 5 | 4 | 4 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $1.43 | $3.23 | $2.58 | $5.32 | $3.02 | $4.01 | - | $2.69 | $3.38 | $3.32 | $0.81 | $2.85 | $2.78 | $3.45 | $3.07 | $3.09 | $2.87 | $3.29 |
| Avg Forecast | $3.94 | $4.95 | $5.03 | $4.65 | $5.41 | $5.55 | $5.51 | $5.04 | $5.43 | $5.14 | $4.98 | $3.88 | $4.59 | $4.67 | $4.49 | $3.85 | $4.10 | $4.47 | $4.43 | $4.10 | $4.04 | $4.29 | $4.09 | $4.05 | $3.36 | $3.93 | $3.82 | $3.74 | $3.41 | $3.53 |
| High Forecast | $4.03 | $5.07 | $5.15 | $4.76 | $5.54 | $5.68 | $5.64 | $5.16 | $5.56 | $5.43 | $5.10 | $3.97 | $5.02 | $4.92 | $4.60 | $3.94 | $4.19 | $4.57 | $4.43 | $4.40 | $4.33 | $4.61 | $4.39 | $4.35 | $3.60 | $4.22 | $4.10 | $4.02 | $3.66 | $3.79 |
| Low Forecast | $3.81 | $4.79 | $4.87 | $4.50 | $5.23 | $5.37 | $5.33 | $4.88 | $5.26 | $4.84 | $4.83 | $3.75 | $4.29 | $4.29 | $4.35 | $3.72 | $3.97 | $4.32 | $4.43 | $3.96 | $3.90 | $4.15 | $3.95 | $3.91 | $3.24 | $3.80 | $3.69 | $3.62 | $3.30 | $3.41 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.31% | 0.69% | 0.57% | 1.38% | 0.74% | 0.90% | - | 0.66% | 0.84% | 0.77% | 0.20% | 0.70% | 0.83% | 0.88% | 0.80% | 0.83% | 0.84% | 0.93% |
According to 9 Wall Street analysts, Amgen's projected average Quarter EPS for Mar 24 is $3.88, with a low estimate of $3.75 and a high estimate of $3.97. This represents a 171.26% increase compared to AMGN previous annual EPS of $1.43 (Dec 23).
Amgen Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PFE | Pfizer | $29.27 | $46.29 | 58.15% | Hold |
| BIIB | Biogen | $195.63 | $291.45 | 48.98% | Buy |
| BMY | Bristol-Myers Squibb Company | $49.13 | $65.43 | 33.18% | Hold |
| MRK | Merck | $115.86 | $127.74 | 10.25% | Buy |
| JNJ | Johnson & Johnson | $165.52 | $176.29 | 6.51% | Buy |
| GILD | Gilead Sciences | $82.81 | $80.00 | -3.39% | Buy |
| AMGN | Amgen | $332.45 | $286.95 | -13.69% | Buy |
| ABBV | AbbVie | $194.21 | $167.54 | -13.73% | Buy |
| LLY | Eli Lilly and Company | $923.71 | $753.65 | -18.41% | Buy |
AMGN Forecast FAQ
Is Amgen a good buy?
Yes, according to 22 Wall Street analysts, Amgen (AMGN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 12 'Buy' recommendations, accounting for 54.55% of AMGN's total ratings.
What is AMGN's price target?
Amgen (AMGN) average price target is $286.95 with a range of $182 to $380, implying a -13.69% from its last price of $332.45. The data is based on 22 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Amgen stock go up soon?
According to Wall Street analysts' prediction for AMGN stock, the company can go down by -13.69% (from the last price of $332.45 to the average price target of $286.95), up by 14.30% based on the highest stock price target, and down by -45.25% based on the lowest stock price target.
Can Amgen stock reach $500?
AMGN's average twelve months analyst stock price target of $286.95 does not support the claim that Amgen can reach $500 in the near future.
What are Amgen's analysts' financial forecasts?
Amgen's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $34.14B (high $34.77B, low $33.3B), average EBITDA is $13.9B (high $14.15B, low $13.56B), average net income is $11.64B (high $11.91B, low $11.26B), average SG&A $7.36B (high $7.49B, low $7.18B), and average EPS is $21.51 (high $22.02, low $20.82). AMGN's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $32.32B (high $32.91B, low $31.52B), average EBITDA is $13.16B (high $13.4B, low $12.83B), average net income is $10.05B (high $10.29B, low $9.73B), average SG&A $6.96B (high $7.09B, low $6.79B), and average EPS is $18.57 (high $19.02, low $17.98).
Did the AMGN's actual financial results beat the analysts' financial forecasts?
Based on Amgen's last annual report (Dec 2023), the company's revenue was $28.19B, beating the average analysts forecast of $27.87B by 1.15%. Apple's EBITDA was $7.9B, missing the average prediction of $11.82B by -33.18%. The company's net income was $6.72B, missing the average estimation of $9B by -25.41%. Apple's SG&A was $6.18B, beating the average forecast of $5.98B by 3.32%. Lastly, the company's EPS was $12.56, missing the average prediction of $17.6 by -28.64%. In terms of the last quarterly report (Dec 2023), Amgen's revenue was $8.2B, beating the average analysts' forecast of $8.13B by 0.86%. The company's EBITDA was $1.27B, missing the average prediction of $3.31B by -61.58%. Amgen's net income was $767M, missing the average estimation of $2.48B by -69.12%. The company's SG&A was $2.27B, beating the average forecast of $1.75B by 29.88%. Lastly, the company's EPS was $1.43, missing the average prediction of $4.59 by -68.85%